Answers are grounded in this paper and cite their sources.
Tumor cell metastasis is the most seriouscomplication in the course of malignant dis -eases. Themolecular mechanisms of metastatictumor spread are complex and not completelyunderstood which complicates pharmacologi-cal antimetastatic approaches. Heparin, the an-ticoagulant drug of choice for more than 70years, possesses antimetastatic effects, andlow-molecular-weight heparins (LMWH)were able to prolong survival in cancer pa-tients in a number of controlled clinical trials[4]. LMWH has no effect on the primary tu-mor but only on the spread of metastases.In addition to the anticoagulatory effectsreducing metastasis, other activities of hepa-rinareassumedtoincludeinhibitionofangio-genesis via the tissue factor pathway inhibi-tor, modulation of growth factor binding andinhibition of heparanase enzymatic activity.Most studies have focused on heparin inter-ference with adhesion receptor P- and L-selectin activity and inhibition of cancer cellinteraction with platelets, leukocytes and theendothelium [1]. Recently we could identifythe integrin VLA-4 (very late activation anti-gen-4, CD29/CD49d), which is expressed onmelanomaandmyelomacells,asafurthertar-get of heparin [2]. The interaction of VLA-4positive MV3 melanomacells with VCAM-1(vascular cell adhesion molecule-1) was im-paired by heparin. For interference withVLA-4 heparin had to exceed a criticalthreshold of saccharide units [7].However, heparin as a glycosaminogly-can is a biopolymer with multiple biologicalactivities.Toutilizetheadvantagesofheparinintumortherapyitisimportanttoseparatetheanticoagulant properties in order to avoidbleeding complications.In the present study we elucidate the ca-pacity of three different non-anticoagulantheparinstoimpairtheVLA-4-mediatedinter-action between MV3 cells and VCAM-1.Two heparins with different degrees of N-acetylation (NA-heparin) and one glycol-split, reduced oxyheparin (RO-heparin) wereapplied.Weprovide evidence thatheparin bindingto VLA-4 is strongly controlled by certainstructural factors, which interestingly, differpartly from the structural requirements for P-and L-selectin inhibition.
No takes yet. Share an insight, caveat, or question.
Schlesinger et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: